Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Other Operating Expenses (2022 - 2026)

Axsome Therapeutics' Other Operating Expenses history spans 5 years, with the latest figure at $16.9 million for Q1 2026.

  • On a quarterly basis, Other Operating Expenses rose 31.18% to $16.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $101.6 million, a 36.87% increase, with the full-year FY2025 number at $51.4 million, down 24.24% from a year prior.
  • Other Operating Expenses hit $16.9 million in Q1 2026 for Axsome Therapeutics, down from $51.1 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for AXSM hit a ceiling of $52.2 million in Q4 2023 and a floor of -$45.3 million in Q3 2022.
  • Historically, Other Operating Expenses has averaged $13.1 million across 5 years, with a median of $12.0 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 90170.07% in 2023 and later crashed 55.73% in 2024.
  • Tracing AXSM's Other Operating Expenses over 5 years: stood at -$57946.0 in 2022, then skyrocketed by 90170.07% to $52.2 million in 2023, then plummeted by 55.73% to $23.1 million in 2024, then soared by 120.98% to $51.1 million in 2025, then tumbled by 66.93% to $16.9 million in 2026.
  • Business Quant data shows Other Operating Expenses for AXSM at $16.9 million in Q1 2026, $51.1 million in Q4 2025, and $26.7 million in Q3 2025.